Unlocking the Full Therapeutic Value of Natural Cell Protection Pathways

OMEICOS is focused on developing therapies that have the potential for a significant impact on cardiovascular, inflammatory and mitochondrial diseases with high unmet need. Our pipeline is based on our proprietary approach to target one of nature’s most important cell-protective pathways and industry-leading knowledge of omega-3 fatty acid metabolism and biology.

Lead compound OMT-28 has recently been tested in a double-blinded, placebo-controlled, multi-center Phase 2 clinical trial in patients suffering from atrial fibrillation. OMT-28 proved its excellent safety and tolerability profile, already shown in Phase I with 75 healthy volunteers.

In addition, the study demonstrated a significant positive effect on a number of inflammatory biomarkers, among them GDF-15 and IL-6, the strongest independent predictors of mortality and disease progression in cardiovascular diseases.

The positive effect of OMT-28 in mitochondrial dysfunction has been demonstrated. Currently, OMEICOS conducts a Phase II proof-of-concept clinical study in myopathy/cardiomyopathy in patients with primary mitochondriopathies.

The company is planning a robust clinical proof-of-concept study to confirm OMT-28’s broad anti-inflammatory effect and to leverage the validated link between reduction of CV inflammation and significant reduction of adverse events in patients with Coronary Artery Disease.

OMT-28 has shown potential for the application to other disease areas such as ophthalmology.